Hua Bai

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, National Cancer Center · ORCID：0000-0002-3179-8137

发表论文 77 篇 · 总被引 2625 次 · h-index 23

代表论文

• Overcoming EGFR-TKI resistance by targeting the tumor microenvironment (2024 · Chinese Medical Journal - Pulmonary and Critical Care Medicine · 被引 32)
• Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy (2024 · Nature Communications · 被引 21)
• Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer (2023 · Frontiers in Immunology · 被引 20)
• Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment (2023 · Thoracic Cancer · 被引 18)
• Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC (2023 · International Journal of Molecular Sciences · 被引 11)
• Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy (2023 · Cell Reports Methods · 被引 11)